Recent Updates
Recently added Catalysts
BBIO Positive Sentiment Score: 78/100

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

Tuesday, September 2, 2025 2 min read
Key Takeaway: BridgeBio Pharma, Inc. has announced that it will present Phase 2 proof-of-concept data for its drug Encaleret, aimed at treating post-surgical hypoparathyroidism, during the ASBMR Annual Meeting 2025 in Seattle. The presentation is scheduled for September 6 and is expected to highlight the drug's effect on reducing urinary calcium while maintaining blood calcium levels. Additionally, the company will present research findings on skeletal dysplasia treatments through poster sessions. This event marks a significant moment for BridgeBio as it showcases advancements in genetic disease therapeutics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of promising Phase 2 data for Encaleret.
  • Involvement of notable researchers and institutions.
  • Opportunity to showcase findings at a prestigious conference.

Full Press Release Details

PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism and two poster sessions on skeletal dysplasia data will be shared at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025, taking place in Seattle, WA from September 5 - 8, 2025.
Post-Surgical Hypoparathyroidism Oral Presentation:
The Oral Calcilytic Encaleret Reduced Urinary Calcium While Maintaining Blood Calcium in Individuals with Post-Surgical Hypoparathyroidism
Presenter: Iris Hartley, M.D., National Institute of Dental and Craniofacial Research, National Institutes of Health
Date/time: Saturday, September 6 at 11:30 am PT
Skeletal Dysplasia Poster Sessions:
Infigratinib Low Dose Therapy Is an Effective Strategy in Improving Bone Growth in a Hypochondroplasia Mouse Model
Presenter: Bhavik Shah, Ph.D., Senior Vice President of Research, Genetic Medicine, Skeletal Dysplasia, BridgeBio
Date/time: Friday, September 5 at 5:00 pm PT and Sunday, September 7 at 2:00 pm PT
Infigratinib Improves Skull Measures in a Mouse Model of Crouzon/Pfeiffer Syndromes
Presenter: Bhavik Shah, Ph.D., Senior Vice President of Research, Genetic Medicine, Skeletal Dysplasia, BridgeBio
Date/time: Saturday, September 6 at 2:00 pm PT
About BridgeBio Pharma, Inc.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance

Frequently Asked Questions

What is the focus of BridgeBio Pharma, Inc.?

BridgeBio Pharma specializes in developing treatments for genetic diseases.

When is the ASBMR Annual Meeting 2025?

The ASBMR Annual Meeting 2025 is from September 5 to 8, 2025, in Seattle.

Who is presenting the Phase 2 data on hypoparathyroidism?

Dr. Iris Hartley from the NIH will present the Phase 2 data.

What does Infigratinib improve in skeletal dysplasia models?

Infigratinib shows improved bone growth and skull measures in mouse models.

How can I contact BridgeBio for media inquiries?

For media inquiries, contact Bubba Murarka at contact@bridgebio.com.

Tags: BBIO Viatris Investor Conferences Healthcare BridgeBio Encaleret hypoparathyroidism ASBMR 2025 skeletal dysplasia
Last updated: Sep 2, 2025